Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 18668017)

1.

Are SNRIs more effective than SSRIs? A review of the current state of the controversy.

Thase ME.

Psychopharmacol Bull. 2008;41(2):58-85. Review.

PMID:
18668017
3.

Milnacipran and selective serotonin reuptake inhibitors in major depression.

Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6. Review.

PMID:
8923126
4.
5.

Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.

Dell'Osso B, Nestadt G, Allen A, Hollander E.

J Clin Psychiatry. 2006 Apr;67(4):600-10. Review.

PMID:
16669725
6.

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.

Machado M, Iskedjian M, Ruiz I, Einarson TR.

Curr Med Res Opin. 2006 Sep;22(9):1825-37.

PMID:
16968586
7.

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.

Lam RW, Lönn SL, Despiégel N.

Int Clin Psychopharmacol. 2010 Jul;25(4):199-203. doi: 10.1097/YIC.0b013e32833948d8.

PMID:
20357664
8.
9.

Escitalopram in the treatment of major depressive disorder: a meta-analysis.

Kennedy SH, Andersen HF, Thase ME.

Curr Med Res Opin. 2009 Jan;25(1):161-75. doi: 10.1185/03007990802622726 .

PMID:
19210149
10.

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.

Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N.

Eur Arch Psychiatry Clin Neurosci. 2009 Apr;259(3):172-85. doi: 10.1007/s00406-008-0849-0. Epub 2009 Jan 22.

PMID:
19165525
11.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Kennedy SH, Andersen HF, Lam RW.

J Psychiatry Neurosci. 2006 Mar;31(2):122-31. Erratum in: J Psychiatry Neurosci. 2006 Jul;31(4):228.

12.

A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.

Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R.

Value Health. 2001 Jan-Feb;4(1):16-31.

PMID:
11704969
13.

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

Smith D, Dempster C, Glanville J, Freemantle N, Anderson I.

Br J Psychiatry. 2002 May;180:396-404. Review.

15.
16.
17.

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

Puech A, Montgomery SA, Prost JF, Solles A, Briley M.

Int Clin Psychopharmacol. 1997 Mar;12(2):99-108.

PMID:
9219045
18.

Meta-analytical studies on new antidepressants.

Anderson IM.

Br Med Bull. 2001;57:161-78. Review.

PMID:
11719915
19.

Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.

Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ.

J Clin Psychopharmacol. 2007 Dec;27(6):672-6.

PMID:
18004135
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk